Skip to main content
SpringerLink
Log in

Type I Insulin-Like Growth Factor Receptor

  • Reference work entry
  • First Online:
Cancer Therapeutic Targets

  • 1851 Accesses

Abstract

The insulin-like growth factor (IGF) system has been implicated in many times of cancer. Upon ligand binding, the type I IGF receptor (IGF1R) transmembrane tyrosine kinase receptor is activated and serves to activate multiple downstream signaling targets. Multiple drugs have been developed to disrupt the function of this receptor, but to date the clinical trial results have been disappointing.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 649.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 949.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Arteaga CL, Kitten LJ, Coronado EB, Jacobs S, Kull Jr FC, Allred DC, Osborne CK. Blockade of the type i somatomedin receptor inhibits growth of human breast cancer cells in athymic mice. J Clin Invest. 1989;84:1418–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform a and insulin-like growth factor ii as additional treatment targets in human osteosarcoma. Cancer Res. 2009;69:2443–52.

    Article  CAS  PubMed  Google Scholar 

  • Carboni JM, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, Hillerman S, Cao C, Cantor GH, Dell-John J, Chen C, Discenza L, Menard K, Li A, Trainor G, Vyas D, Kramer R, Attar RM, Gottardis MM. Bms-754807, a small molecule inhibitor of insulin-like growth factor-1r/ir. Mol Cancer Ther. 2009;8:3341–9.

    Article  CAS  PubMed  Google Scholar 

  • Coppola D, Ferber A, Miura M, Sell C, Dambrosio C, Rubin R, Baserga R. A functional insulin-like growth factor i receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol Cell Biol. 1994;14:4588–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Creighton CJ, Casa A, Lazard Z, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Lee AV. Insulin-like growth factor-i activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol. 2008;26:4078–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L. A human monoclonal antibody against insulin-like growth factor-ii blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo. Mol Cancer Ther. 2010;9:1809–19.

    Article  CAS  PubMed  Google Scholar 

  • Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A, Rzyman W, Dziadziuszko K, Jassem J, Bunn Jr PA, Varella-Garcia M, Hirsch FR. Insulin-like growth factor receptor 1 (igf1r) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between igf1r fluorescent in situ hybridization, protein expression, and mrna expression. J Clin Oncol. 2010;28:2174–80.

    Article  PubMed  PubMed Central  Google Scholar 

  • Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (osi-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–35.

    Article  CAS  PubMed  Google Scholar 

  • Friedbichler K, Hofmann MH, Kroez M, Ostermann E, Lamche HR, Koessl C, Borges E, Pollak MN, Adolf G, Adam PJ. Pharmacodynamic and antineoplastic activity of bi 836845, a fully human igf ligand-neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther. 2014;13:399–409.

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Echeverria C, Pearson MA, Marti A, Meyer T, Mestan J, Zimmermann J, Gao J, Brueggen J, Capraro HG, Cozens R, Evans DB, Fabbro D, Furet P, Porta DG, Liebetanz J, Martiny-Baron G, Ruetz S, Hofmann F. In vivo antitumor activity of nvp-aew541-a novel, potent, and selective inhibitor of the igf-ir kinase. Cancer Cell. 2004;5:231–9.

    Article  CAS  PubMed  Google Scholar 

  • Goya M, Miyamoto S, Nagai K, Ohki Y, Nakamura K, Shitara K, Maeda H, Sangai T, Kodama K, Endoh Y, Ishii G, Hasebe T, Yonou H, Hatano T, Ogawa Y, Ochiai A. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 2004;64:6252–8.

    Article  CAS  PubMed  Google Scholar 

  • Graff JN, Thomas GV, Higano CS, Beer TM. Prolonged response to an igf-1 receptor antibody in a patient with metastatic castration prostate cancer with neuroendocrine differentiation. Cureus. 2015;7:e426.

    PubMed  PubMed Central  Google Scholar 

  • Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase i dose escalation study of the anti insulin-like growth factor-i receptor monoclonal antibody cp-751,871 in patients with refractory solid tumors. Clin Cancer Res. 2007;13:5834–40.

    Article  CAS  PubMed  Google Scholar 

  • Iams WT, Lovly CM. Molecular pathways: clinical applications and future direction of insulin-like growth factor-1 receptor pathway blockade. Clin Cancer Res. 2015;21:4270–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Iguchi H, Nishina T, Nogami N, Kozuki T, Yamagiwa Y, Yagawa K. Phase i dose-escalation study evaluating safety, tolerability and pharmacokinetics of medi-573, a dual igf-i/ii neutralizing antibody, in japanese patients with advanced solid tumours. Invest New Drugs. 2015;33:194–200.

    Article  CAS  PubMed  Google Scholar 

  • Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, O’Connor M, Yao Y, Pirritt C, Buck E, Eyzaguirre A, Arnold LD, Gibson NW, Pachter JA. A novel, potent, and selective insulin-like growth factor-i receptor kinase inhibitor blocks insulin-like growth factor-i receptor signaling in vitro and inhibits insulin-like growth factor-i receptor dependent tumor growth in vivo. Mol Cancer Ther. 2007;6:2158–67.

    Article  CAS  PubMed  Google Scholar 

  • Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens A, Simantov R, Poondru S, Gedrich R, Lipman SM, Kaye SB, Carden CP. Phase i study of intermittent oral dosing of the insulin-like growth factor-1 and insulin receptors inhibitor osi-906 in patients with advanced solid tumors. Clin Cancer Res. 2015;21:693–700.

    Article  CAS  PubMed  Google Scholar 

  • Kaletsky R, Murphy CT. The role of insulin/igf-like signaling in C. elegans longevity and aging. Dis Model Mech. 2010;3:415–9.

    Article  CAS  PubMed  Google Scholar 

  • Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase i, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody cp-751,871 in patients with multiple myeloma. J Clin Oncol. 2008;26:3196–203.

    Article  CAS  PubMed  Google Scholar 

  • Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008;68:10238–46.

    Article  CAS  PubMed  Google Scholar 

  • Litzenburger BC, Kim HJ, Kuiatse I, Carboni JM, Attar RM, Gottardis MM, Fairchild CR, Lee AV. Bms-536924 reverses igf-ir-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of mcf7 cells. Clin Cancer Res. 2009;15:226–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McCaffery I, Tudor Y, Deng H, Tang R, Suzuki S, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, Chen L, Gansert JL. Putative predictive biomarkers of survival in patients with metastatic pancreatic adenocarcinoma treated with gemcitabine and ganitumab, an igf1r inhibitor. Clin Cancer Res. 2013;19:4282–9.

    Article  CAS  PubMed  Google Scholar 

  • McKian KP, Haluska P. Cixutumumab. Expert Opin Investig Drugs. 2009;18:1025–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Papa V, Gliozzo B, Clark GM, McGuire WL, Moore D, Fujita-Yamaguchi Y, Vigneri R, Goldfine ID, Pezzino V. Insulin-like growth factor-i receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res. 1993;53:3736–40.

    CAS  PubMed  Google Scholar 

  • Pitts TM, Tan AC, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, Leong S, Coldren CD, Hirsch FR, Varella-Garcia M, Korch C, Eckhardt SG. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res. 2010;16:3193–204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Puzanov I, Lindsay C, Goff LW, Sosman JA, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase i study of continuous oral dosing of osi-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors in patients with advanced solid tumors. Clin Cancer Res. 2015;21:701–11.

    Article  CAS  PubMed  Google Scholar 

  • Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (igf)-i, igf binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363:1346–53.

    Article  CAS  PubMed  Google Scholar 

  • Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther. 2007;6:1–12.

    Article  CAS  PubMed  Google Scholar 

  • Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D. A chimeric humanized single-chain antibody against the type i insulin-like growth factor (igf) receptor renders breast cancer cells refractory to the mitogenic effects of igf-i. Cancer Res. 2003;63:627–35.

    CAS  PubMed  Google Scholar 

  • Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu S. Dalotuzumab, a recombinant humanized mab targeted against igfr1 for the treatment of cancer. Curr Opin Mol Ther. 2010;12:361–71.

    CAS  PubMed  Google Scholar 

  • Soos MA, Whittaker J, Lammers R, Ullrich A, Siddle K. Receptors for insulin and insulin-like growth factor-i can form hybrid dimers, characterisation of hybrid receptors in transfected cells. Biochem J. 1990;270:383–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Steele-Perkins G, Turner J, Edman JC, Hari J, Pierce SB, Stover C, Rutter WJ, Roth RA. Expression and characterization of a functional human insulin-like growth factor i receptor. J Biol Chem. 1988;263:11486–92.

    CAS  PubMed  Google Scholar 

  • Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A. Phase ii study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic ewing family tumors or desmoplastic small round cell tumors. J Clin Oncol. 2012;30:1849–56.

    Article  CAS  PubMed  Google Scholar 

  • Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I. Phase i, pharmacokinetic, and pharmacodynamic study of amg 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27:5800–7.

    Article  CAS  PubMed  Google Scholar 

  • Treadway JL, Morrison BD, Soos MA, Siddle K, Olefsky J, Ullrich A, McClain DA, Pessin JE. Transdominant inhibition of tyrosine kinase activity in mutant insulin/insulin-like growth factor i hybrid receptors. Proc Natl Acad Sci U S A. 1991;88:214–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Valentinis B, Porcu P, Quinn K, Baserga R. The role of the insulin-like growth factor i receptor in the transformation by simian virus 40 t antigen. Oncogene. 1994;9:825–31.

    CAS  PubMed  Google Scholar 

  • Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16:1103–23.

    Article  CAS  PubMed  Google Scholar 

  • Vijayakumar A, Novosyadlyy R, Wu Y, Yakar S, LeRoith D. Biological effects of growth hormone on carbohydrate and lipid metabolism. Growth Horm IGF Res. 2010;20:1–7.

    Article  CAS  PubMed  Google Scholar 

  • Yee D. A tale of two receptors: insulin and insulin-like growth factor signaling in cancer. Clin Cancer Res. 2015;21:667–9.

    Article  CAS  PubMed  Google Scholar 

  • Yee D, Favoni RE, Lebovic GS, Lombana F, Powell DR, Reynolds CP, Rosen N. Insulin-like growth factor i expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor. J Clin Invest. 1990;86:1806–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang H, Sachdev D, Wang C, Hubel A, Gaillard-Kelly M, Yee D. Detection and downregulation of type i igf receptor expression by antibody-conjugated quantum dots in breast cancer cells. Breast Cancer Res Treat. 2009;114:277–85.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

    Douglas Yee

Authors
  1. Douglas Yee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas Yee .

Editor information

Editors and Affiliations

  1. Division of Hematology & Oncology, Georgetown Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, USA

    John L. Marshall

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer Science+Business Media New York

About this entry

Cite this entry

Yee, D. (2017). Type I Insulin-Like Growth Factor Receptor. In: Marshall, J. (eds) Cancer Therapeutic Targets. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0717-2_3

Download citation

Publish with us

Policies and ethics

Search

Navigation